BioSpace News Archive

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2021 and provided a company update.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the first cohort of healthy volunteers has been dosed in its Phase 1 trial of CD388.

VBL Therapeutics today announced that it will host a key opinion leader (KOL) luncheon and seminar on ovarian cancer on Monday, April 11, 2022 at 12pm Eastern Time at the St. Regis Hotel in New York, NY.

CHARGE syndrome, which affects approximately one in 10,000 newborns worldwide, is associated with neurological and behavioural conditions like intellectual disability, attention deficit disorder, convulsions, and autism.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the launch of Save Legs.

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces the publication of a peer-reviewed study in the Advances in Wound Care Journal reporting outcomes for Medicare patients with a diabetic foot ulcer (DFU) that shows GRAFIX Cryopreserved Placental Membrane cut DFU recurrence rates in half compared to leading cellular and tissue-based product (CTP) competitors.

China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced financial results for the fiscal year ended December 31, 2021.

I-Mab today announced that the Company’s key shareholders including CBC Group (including its affiliates) and Hony Capital (collectively, the “Key Shareholders”) as well as its senior management team have voluntarily entered into a 180-days lock-up period commencing from March 31, 2022.

Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it has entered into an exclusive option and research collaboration agreement with Prime Medicine, Inc. (“Prime”), a company founded to deliver on the promise of Prime Editing.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the company will present research from its robust neurology portfolio, including the findings on lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody being developed for the treatment of early Alzheimer’s disease (AD) at the American Academy.